April 25, 2025 07:43 AM EDT

AbbVie's immunology franchise remains a powerhouse, as Skyrizi, Rinvoq combine for $5B

Max Gelman

Senior Editor

One quarter after AbbVie raised future sales estimates due to the successes of its immunology portfolio, the company again saw higher-than-expected revenues …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie's immunology franchise remains a powerhouse, as Skyrizi, Rinvoq combine for $5B

Max Gelman

Senior Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

Merck KGaA closes in on SpringWorks deal at $3.5B price point

Paul Stoffels on retiring from Galapagos; Boehringer Ingelheim switches up leadership

Versant's latest biotech focuses on inflammatory diseases

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Ab­b­Vie's im­munol­o­gy fran­chise re­mains a pow­er­house, as Skyrizi, Rin­voq com­bine for $5B

Senior Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

AbbVie's immunology franchise remains a powerhouse, as Skyrizi, Rinvoq combine for $5B